source
- Few European-approved cancer drugs deliver high clinical benefit, analysis showsA new analysis of European regulator approvals between Jan 2022 and July 2026 finds that most newly approved cancer medicines provide limited clinical benefit. Out of 97 approved indications acros…
- Novartis MS drug remibrutinib cuts relapse rates by about a third in Phase 3 trialsData presented at an MS conference in Toronto showed that Novartis' experimental therapy, remibrutinib, reduced the annualized relapse rate in relapsing‑remitting multiple sclerosis by roughly 35%…